Clinical Perspectives in Pulmonary Arterial Hypertension

A Journal Scan supplement to Cardiology News. This promotional supplement was sponsored by Actelion Pharmaceuticals Ltd.

• Introduction
• Managing PAH - A Cardiologist's Perspective and A Pulmonologist's Perspective
• Clinical Classification of Pulmonary Arterial Hypertension
• Targeting Endothelin-1 in PAH With Bosentan
• Bosentan Therapy For Pulmonary Arterial Hypertension
• Treatment of Functional Class II PAH With Bosentan
• Treatment of Eisenmenger Syndrome with Bosentan
• Safety Profile Information

Faculty/Faculty Disclosures

Vallerie McLaughlin, MD
Professor of Medicine
University of Michigan
Ann Arbor, MI
Dr McLaughlin is a consultant to Actelion Pharmaceuticals Ltd., and Gilead, and has received funding for clinical grants from Actelion and United Therapeutics Corporation.

Richard Channick, MD
Director, Pulmonary Hypertension
Program, Massachusetts General
Hospital, Harvard Medical School
Boston, MA
Dr Channick is a consultant to, and has received funding for clinical grants from Actelion Pharmaceuticals Ltd., Gilead, and United Therapeutics Corporation.

To view the supplement, click the image above.

A Journal Scan supplement to Cardiology News. This promotional supplement was sponsored by Actelion Pharmaceuticals Ltd.

• Introduction
• Managing PAH - A Cardiologist's Perspective and A Pulmonologist's Perspective
• Clinical Classification of Pulmonary Arterial Hypertension
• Targeting Endothelin-1 in PAH With Bosentan
• Bosentan Therapy For Pulmonary Arterial Hypertension
• Treatment of Functional Class II PAH With Bosentan
• Treatment of Eisenmenger Syndrome with Bosentan
• Safety Profile Information

Faculty/Faculty Disclosures

Vallerie McLaughlin, MD
Professor of Medicine
University of Michigan
Ann Arbor, MI
Dr McLaughlin is a consultant to Actelion Pharmaceuticals Ltd., and Gilead, and has received funding for clinical grants from Actelion and United Therapeutics Corporation.

Richard Channick, MD
Director, Pulmonary Hypertension
Program, Massachusetts General
Hospital, Harvard Medical School
Boston, MA
Dr Channick is a consultant to, and has received funding for clinical grants from Actelion Pharmaceuticals Ltd., Gilead, and United Therapeutics Corporation.

To view the supplement, click the image above.

A Journal Scan supplement to Cardiology News. This promotional supplement was sponsored by Actelion Pharmaceuticals Ltd.

• Introduction
• Managing PAH - A Cardiologist's Perspective and A Pulmonologist's Perspective
• Clinical Classification of Pulmonary Arterial Hypertension
• Targeting Endothelin-1 in PAH With Bosentan
• Bosentan Therapy For Pulmonary Arterial Hypertension
• Treatment of Functional Class II PAH With Bosentan
• Treatment of Eisenmenger Syndrome with Bosentan
• Safety Profile Information

Faculty/Faculty Disclosures

Vallerie McLaughlin, MD
Professor of Medicine
University of Michigan
Ann Arbor, MI
Dr McLaughlin is a consultant to Actelion Pharmaceuticals Ltd., and Gilead, and has received funding for clinical grants from Actelion and United Therapeutics Corporation.

Richard Channick, MD
Director, Pulmonary Hypertension
Program, Massachusetts General
Hospital, Harvard Medical School
Boston, MA
Dr Channick is a consultant to, and has received funding for clinical grants from Actelion Pharmaceuticals Ltd., Gilead, and United Therapeutics Corporation.

To view the supplement, click the image above.